This thesis provides a comprehensive overview of current and emerging pharmacological strategies in the management of chronic kidney disease (CKD). It effectively addresses the multifaceted complications associated with CKD, including cardiovascular disease, anaemia, mineral-bone disorders, hyperkalaemia, and inflammation. The work highlights the nephroprotective benefits of established therapies like SGLT2 inhibitors and RAAS blockers, while also exploring newer treatments such as HIF-PH inhibitors, potassium binders, and endothelin receptor antagonists. Notably, the thesis discusses innovative prospects like gene therapy and regenerative medicine, showing a forward-thinking approach to CKD management. The content is well-researched, clearly structured, and reflects a strong understanding of both clinical and pharmacological aspects of the disease. Overall, it is a valuable contribution that bridges current practice with future therapeutic directions in nephrology.